MIRA
INFORM REPORT
|
Report Date : |
24.05.2013 |
IDENTIFICATION DETAILS
|
Name : |
MERCKLE GMBH
|
|
|
|
|
Registered Office : |
Ludwig-Merckle-Strasse 3, Blaubeuren, 89143 |
|
|
|
|
Country : |
Germany |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
22.02.2005 |
|
|
|
|
Com. Reg. No.: |
5125 |
|
|
|
|
Legal Form : |
Private Subsidiary Company |
|
|
|
|
Line of Business : |
manufacturer of medicaments; and manufacture of
non-medicaments. |
|
|
|
|
No. of Employees : |
1,670 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Germany |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
germany ECONOMIC OVERVIEW
The German
economy - the fifth largest economy in the world in PPP terms and Europe's
largest - is a leading exporter of machinery, vehicles, chemicals, and
household equipment and benefits from a highly skilled labor force. Like its
Western European neighbors, Germany faces significant demographic challenges to
sustained long-term growth. Low fertility rates and declining net immigration
are increasing pressure on the country's social welfare system and necessitate
structural reforms. Reforms launched by the government of Chancellor Gerhard
SCHROEDER (1998-2005), deemed necessary to address chronically high
unemployment and low average growth, contributed to strong growth in 2006 and
2007 and falling unemployment. These advances, as well as a government
subsidized, reduced working hour scheme, help explain the relatively modest
increase in unemployment during the 2008-09 recession - the deepest since World
War II - and its decrease to 6.5% in 2012. GDP contracted 5.1% in 2009 but grew
by 4.2% in 2010, and 3.0% in 2011, before dipping to 0.7% in 2012 - a
reflection of low investment spending due to crisis-induced uncertainty and the
decreased demand for German exports from recession-stricken periphery
countries. Stimulus and stabilization efforts initiated in 2008 and 2009 and
tax cuts introduced in Chancellor Angela MERKEL's second term increased
Germany's total budget deficit - including federal, state, and municipal - to
4.1% in 2010, but slower spending and higher tax revenues reduced the deficit
to 0.8% in 2011. In 2012 Germany reached a budget surplus of 0.1%. A
constitutional amendment approved in 2009 limits the federal government to
structural deficits of no more than 0.35% of GDP per annum as of 2016 though
the target was already reached in 2012. By 2014, the federal government wants
to balance its budget. Following the March 2011 Fukushima nuclear disaster,
Chancellor Angela Merkel announced in May 2011 that eight of the country's 17
nuclear reactors would be shut down immediately and the remaining plants would
close by 2022. Germany hopes to replace nuclear power with renewable energy.
Before the shutdown of the eight reactors, Germany relied on nuclear power for
23% of its electricity generating capacity and 46% of its base-load electricity
production.
|
Source
: CIA |
Company name & address
Merckle GmbH
Ludwig-Merckle-Strasse 3
Blaubeuren, 89143
Germany
Tel: +49 (0) 7344 140
Fax: +49 (0) 7344 141620
Synthesis
Employees: 1,670
Company Type: Private Subsidiary
Corporate Family: 172
Companies
Ultimate Parent: Teva Pharmaceutical Industries
Limited
Incorporation Date:
22-Feb-2005
Financials in: USD
(Millions)
Fiscal Year End:
31-Dec-2011
Reporting Currency: Euro
Annual Sales: 1,193.8
Total Assets: 3,626.2
Business Description
Merckle GmbH is primarily engaged in manufacture of medicaments; and
manufacture of non-medicaments.
Industry
Industry Biotechnology and Drugs
ANZSIC 2006: 1841 - Human
Pharmaceutical and Medicinal Product Manufacturing
NACE 2002: 2442 - Manufacture
of pharmaceutical preparations
NAICS 2002: 325412 -
Pharmaceutical Preparation Manufacturing
UK SIC 2003: 2442 - Manufacture
of pharmaceutical preparations
UK SIC 2007: 2120 - Manufacture
of pharmaceutical preparations
US SIC 1987: 2834 -
Pharmaceutical Preparations
Key Executives
|
Name |
Title |
|
Walter BUhl |
Managing director |
|
Sven Dethlefs |
Managing director |
|
Stefan Feltens |
Managing director |
|
Gerald Huber |
Managing director |
|
Rob Koremans |
Managing director |
1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7191895
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.770327
Corporate Overview
Location
Ludwig-Merckle-Strasse 3
Blaubeuren, 89143
Germany
Tel: +49 (0) 7344 140
Fax: +49 (0) 7344 141620
Sales EUR(mil): 858.6
Assets EUR(mil): 2,793.3
Employees: 1,670
Fiscal Year End: 31-Dec-2011
Industry: Biotechnology and Drugs
Incorporation Date: 22-Feb-2005
Company Type: Private Subsidiary
Quoted Status: Not Quoted
Registered No.(DEU): 5125
Managing director: Walter BUhl
Industry Codes
ANZSIC 2006 Codes:
1841 - Human Pharmaceutical and Medicinal Product Manufacturing
3720 - Pharmaceutical and Toiletry Goods Wholesaling
NACE 2002 Codes:
2442 - Manufacture of pharmaceutical preparations
5146 - Wholesale of pharmaceutical goods
NAICS 2002 Codes:
325412 - Pharmaceutical Preparation Manufacturing
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
US SIC 1987:
2834 - Pharmaceutical Preparations
5122 - Drugs, Drug Proprietaries, and Druggists' Sundries
UK SIC 2003:
2442 - Manufacture of pharmaceutical preparations
5146 - Wholesale of pharmaceutical goods
UK SIC 2007:
2120 - Manufacture of pharmaceutical preparations
4646 - Wholesale of pharmaceutical goods
Business
Description
Merckle GmbH is primarily engaged in manufacture of medicaments; and
manufacture of non-medicaments.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Corporate Family |
Corporate
Structure News: |
|
|
Teva
Pharmaceutical Industries Limited |
|
Merckle GmbH |
|
|
|
|
|
Company
Name |
Company
Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
Parent |
Petah Tikva |
Israel |
Biotechnology and Drugs |
18,312.0 |
45,754 |
||
|
Subsidiary |
Miami, FL |
United States |
Miscellaneous Financial Services |
|
10,100 |
||
|
Subsidiary |
Opava |
Czech Republic |
Biotechnology and Drugs |
440.8 |
1,458 |
||
|
Subsidiary |
Miami, FL |
United States |
Biotechnology and Drugs |
|
1,000 |
||
|
Subsidiary |
Santiago |
Chile |
Biotechnology and Drugs |
|
1,000 |
||
|
Subsidiary |
Lima |
Peru |
Biotechnology and Drugs |
|
1,000 |
||
|
Subsidiary |
Saint Joseph, MO |
United States |
Biotechnology and Drugs |
|
250 |
||
|
Subsidiary |
Carapachay, Buenos Aires |
Argentina |
Biotechnology and Drugs |
71.0 |
200 |
||
|
Subsidiary |
Montevideo |
Uruguay |
Biotechnology and Drugs |
|
100 |
||
|
Subsidiary |
Miami, FL |
United States |
Biotechnology and Drugs |
16.8 |
87 |
||
|
Subsidiary |
Miami, FL |
United States |
Biotechnology and Drugs |
|
75 |
||
|
Subsidiary |
Rome |
Italy |
Biotechnology and Drugs |
5.2 |
30 |
||
|
Subsidiary |
Springdale, AR |
United States |
Biotechnology and Drugs |
|
7 |
||
|
Subsidiary |
Ulm |
Germany |
Biotechnology and Drugs |
2,420.4 |
5,584 |
||
|
Subsidiary |
Mississauga, ON |
Canada |
Biotechnology and Drugs |
|
400 |
||
|
Subsidiary |
Vienna |
Austria |
Biotechnology and Drugs |
64.5 |
65 |
||
|
Subsidiary |
Bruxelles |
Belgium |
Biotechnology and Drugs |
0.3 |
20 |
||
|
Subsidiary |
Horsholm |
Denmark |
Biotechnology and Drugs |
0.0 |
5 |
||
|
Subsidiary |
Prague |
Czech Republic |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Lees Summit, MO |
United States |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Frazer, PA |
United States |
Biotechnology and Drugs |
2,811.1 |
3,726 |
||
|
Subsidiary |
Aesch |
Switzerland |
Biotechnology and Drugs |
|
500 |
||
|
Subsidiary |
Eden Prairie, MN |
United States |
Biotechnology and Drugs |
|
350 |
||
|
Subsidiary |
Salt Lake City, UT |
United States |
Biotechnology and Drugs |
9.1 |
300 |
||
|
Subsidiary |
Brooklyn Park, MN |
United States |
Biotechnology and Drugs |
|
110 |
||
|
Branch |
Salt Lake City, UT |
United States |
Biotechnology and Drugs |
13.7 |
15 |
||
|
Subsidiary |
Malvern, PA |
United States |
Biotechnology and Drugs |
3.0 |
75 |
||
|
Subsidiary |
Macquarie, NSW |
Australia |
Business Services |
50.7 |
50 |
||
|
Subsidiary |
Castleford |
United Kingdom |
Commercial Banks |
|
|
||
|
Subsidiary |
Hertfordshire |
United Kingdom |
Business Services |
|
25 |
||
|
Subsidiary |
Maisons-Alfort |
France |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Maisons Alfort |
France |
Biotechnology and Drugs |
307.2 |
545 |
||
|
Subsidiary |
Castleford |
United Kingdom |
Retail (Specialty) |
67.5 |
53 |
||
|
Subsidiary |
Ulm |
Germany |
Biotechnology and Drugs |
|
30 |
||
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
|
10 |
||
|
Subsidiary |
Bergeijk |
Netherlands |
Biotechnology and Drugs |
|
2 |
||
|
Subsidiary |
Sant Cugat del Valles |
Spain |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Rome |
Italy |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Ulm, Baden-WUrttemberg |
Germany |
Personal and Household Products |
883.9 |
2,760 |
||
|
Subsidiary |
Alcobendas, Madrid |
Spain |
Personal and Household Products |
166.8 |
126 |
||
|
Subsidiary |
Ulm, Baden-WUrttemberg |
Germany |
Biotechnology and Drugs |
|
40 |
||
|
Subsidiary |
Blaubeuren, Baden-WUrttemberg |
Germany |
Biotechnology and Drugs |
1,193.8 |
2,750 |
||
|
Subsidiary |
Ulm, Baden-WUrttemberg |
Germany |
Biotechnology and Drugs |
13.0 |
80 |
||
|
Subsidiary |
Zagreb |
Croatia |
Biotechnology and Drugs |
|
2,000 |
||
|
Subsidiary |
Zagreb |
Croatia |
Biotechnology and Drugs |
450.9 |
1,696 |
||
|
Subsidiary |
North Wales, PA |
United States |
Biotechnology and Drugs |
4,798.9 |
1,500 |
||
|
Branch |
Irvine, CA |
United States |
Biotechnology and Drugs |
855.4 |
950 |
||
|
Subsidiary |
Castleford |
United Kingdom |
Biotechnology and Drugs |
611.4 |
665 |
||
|
Subsidiary |
Aylesbury |
United Kingdom |
Biotechnology and Drugs |
17.1 |
35 |
||
|
Subsidiary |
Castleford |
United Kingdom |
Biotechnology and Drugs |
|
|
||
|
Affiliates |
Birmingham |
United Kingdom |
Nonclassifiable Industries |
|
|
||
|
Unit |
Runcorn |
United Kingdom |
Biotechnology and Drugs |
|
|
||
|
Branch |
Cincinnati, OH |
United States |
Biotechnology and Drugs |
175.0 |
400 |
||
|
Subsidiary |
North Wales, PA |
United States |
Personal and Household Products |
|
350 |
||
|
Branch |
Doral, FL |
United States |
Biotechnology and Drugs |
234.9 |
300 |
||
|
Branch |
Fairfield, NJ |
United States |
Biotechnology and Drugs |
249.1 |
250 |
||
|
Branch |
Ramsey, NJ |
United States |
Biotechnology and Drugs |
249.1 |
250 |
||
|
Branch |
Forest, VA |
United States |
Biotechnology and Drugs |
221.0 |
250 |
||
|
Branch |
Pomona, NY |
United States |
Biotechnology and Drugs |
202.3 |
250 |
||
|
Branch |
Blauvelt, NY |
United States |
Biotechnology and Drugs |
202.3 |
250 |
||
|
Branch |
Boston, MA |
United States |
Biotechnology and Drugs |
198.3 |
250 |
||
|
Branch |
Washington, DC |
United States |
Biotechnology and Drugs |
109.6 |
250 |
||
|
Branch |
Fairfield, NJ |
United States |
Biotechnology and Drugs |
249.1 |
100 |
||
|
Branch |
Mexico, MO |
United States |
Biotechnology and Drugs |
70.6 |
92 |
||
|
Subsidiary |
North Wales, PA |
United States |
Biotechnology and Drugs |
|
60 |
||
|
Branch |
North Tonawanda, NY |
United States |
Biotechnology and Drugs |
|
10 |
||
|
Branch |
Shawnee Mission, KS |
United States |
Personal and Household Products |
18.4 |
8 |
||
|
Branch |
Potomac, MD |
United States |
Biotechnology and Drugs |
215.3 |
1 |
||
|
Subsidiary |
Komarov |
Czech Republic |
Biotechnology and Drugs |
|
800 |
||
|
Subsidiary |
Haarlem |
Netherlands |
Biotechnology and Drugs |
|
600 |
||
|
Subsidiary |
Haarlem, Noord-Holland |
Netherlands |
Biotechnology and Drugs |
58.4 |
|
||
|
Subsidiary |
Haarlem, Noord-Holland |
Netherlands |
Personal and Household Products |
|
29 |
||
|
Subsidiary |
Haarlem, Noord-Holland |
Netherlands |
Personal and Household Products |
|
|
||
|
Subsidiary |
Netanya |
Israel |
Biotechnology and Drugs |
|
600 |
||
|
Subsidiary |
Alcobendas, Madrid |
Spain |
Biotechnology and Drugs |
378.6 |
548 |
||
|
Subsidiary |
Toronto, ON |
Canada |
Biotechnology and Drugs |
|
500 |
||
|
Subsidiary |
Markham, ON |
Canada |
Biotechnology and Drugs |
227.5 |
180 |
||
|
Subsidiary |
Wembley |
United Kingdom |
Business Services |
|
|
||
|
Subsidiary |
Koka, Shiga |
Japan |
Biotechnology and Drugs |
|
400 |
||
|
Subsidiary |
Monte Carlo |
Monaco |
Biotechnology and Drugs |
|
390 |
||
|
Subsidiary |
Paris La DĂ©fense |
France |
Biotechnology and Drugs |
616.9 |
374 |
||
|
Branch |
Sens, Yonne |
France |
Biotechnology and Drugs |
|
50 |
||
|
Subsidiary |
Radebeul, Sachsen |
Germany |
Biotechnology and Drugs |
134.3 |
300 |
||
|
Subsidiary |
Ulm, Baden-WUrttemberg |
Germany |
Personal and Household Products |
79.1 |
10 |
||
|
Subsidiary |
Netanya |
Israel |
Biotechnology and Drugs |
|
260 |
||
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
|
260 |
||
|
Subsidiary |
Ulm, Baden-WUrttemberg |
Germany |
Biotechnology and Drugs |
252.6 |
204 |
||
|
Subsidiary |
Mexico, Huixquilucan |
Mexico |
Biotechnology and Drugs |
|
180 |
||
|
Subsidiary |
Lerma |
Mexico |
Biotechnology and Drugs |
|
135 |
||
|
Subsidiary |
Netanya |
Israel |
Personal and Household Products |
|
100 |
||
|
Subsidiary |
Ulm, Baden-WUrttemberg |
Germany |
Miscellaneous Capital Goods |
46.2 |
89 |
||
|
Subsidiary |
Wilrijk |
Belgium |
Biotechnology and Drugs |
46.4 |
79 |
||
|
Subsidiary |
Buenos Aires |
Argentina |
Biotechnology and Drugs |
|
70 |
||
|
Subsidiary |
Utrecht |
Netherlands |
Miscellaneous Financial Services |
433.5 |
50 |
||
|
Subsidiary |
Budapest |
Hungary |
Personal and Household Products |
1,253.8 |
2,753 |
||
|
Pliva
Hungaria Kereskedelmi Es Szolgaltato Korlatolt Felelossegu Tarsasag |
Subsidiary |
Budapest |
Hungary |
Personal and Household Products |
6.1 |
4 |
|
|
Subsidiary |
Debrecen |
Hungary |
Biotechnology and Drugs |
776.1 |
|
||
|
Subsidiary |
Warszawa |
Poland |
Business Services |
86.2 |
600 |
||
|
Subsidiary |
Debrecen |
Hungary |
Biotechnology and Drugs |
|
600 |
||
|
Subsidiary |
Milan |
Italy |
Biotechnology and Drugs |
397.1 |
354 |
||
|
Subsidiary |
Settimo Milanese, MI |
Italy |
Biotechnology and Drugs |
|
50 |
||
|
Subsidiary |
Milan |
Italy |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Godollo |
Hungary |
Biotechnology and Drugs |
|
300 |
||
|
Subsidiary |
Seregno |
Italy |
Biotechnology and Drugs |
135.1 |
237 |
||
|
Unit |
Moscow |
Russian Federation |
Biotechnology and Drugs |
|
200 |
||
|
Subsidiary |
Prague |
Czech Republic |
Biotechnology and Drugs |
|
180 |
||
|
Subsidiary |
Praha 5 |
Czech Republic |
Personal and Household Products |
231.5 |
161 |
||
|
Subsidiary |
Madrid |
Spain |
Biotechnology and Drugs |
|
150 |
||
|
Subsidiary |
Bratislava |
Slovakia |
Biotechnology and Drugs |
|
150 |
||
|
Subsidiary |
La Defense |
France |
Biotechnology and Drugs |
|
120 |
||
|
Subsidiary |
Radebeul |
Germany |
Biotechnology and Drugs |
|
80 |
||
|
Subsidiary |
Sao Paulo, Sao Paulo |
Brazil |
Medical Equipment and Supplies |
|
40 |
||
|
Subsidiary |
Espoo |
Finland |
Biotechnology and Drugs |
69.3 |
30 |
||
|
Subsidiary |
Linda-a-Velha |
Portugal |
Biotechnology and Drugs |
|
30 |
||
|
Subsidiary |
Sofia |
Bulgaria |
Biotechnology and Drugs |
|
30 |
||
|
Subsidiary |
Helsingborg |
Sweden |
Biotechnology and Drugs |
|
20 |
||
|
Subsidiary |
Utrecht, Utrecht |
Netherlands |
Personal and Household Products |
|
8 |
||
|
Subsidiary |
Castleford |
United Kingdom |
Business Services |
|
|
||
|
Subsidiary |
Castleford |
United Kingdom |
Business Services |
|
|
||
|
Subsidiary |
Castleford |
United Kingdom |
Biotechnology and Drugs |
11.0 |
|
||
|
Subsidiary |
Castleford |
United Kingdom |
Personal and Household Products |
7.2 |
|
||
|
Subsidiary |
Castleford |
United Kingdom |
Biotechnology and Drugs |
0.3 |
|
||
|
Subsidiary |
Utrecht |
Netherlands |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Lugano |
Switzerland |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Bucharest |
Romania |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Barcelona |
Spain |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Radebeul |
Germany |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Utrecht, Utrecht |
Netherlands |
Personal and Household Products |
|
|
||
|
Subsidiary |
Istanbul (Europe) |
Turkey |
Medical Equipment and Supplies |
|
110 |
||
|
Subsidiary |
Ljubljana-Crnuce |
Slovenia |
Personal and Household Products |
19.5 |
33 |
||
|
Subsidiary |
Woodcliff Lake, NJ |
United States |
Biotechnology and Drugs |
|
50 |
||
|
Subsidiary |
Kansas City, MO |
United States |
Biotechnology and Drugs |
19.3 |
350 |
||
|
Branch |
Montreal, QC |
Canada |
Personal and Household Products |
153.2 |
83 |
||
|
Subsidiary |
Rockville, MD |
United States |
Biotechnology and Drugs |
|
77 |
||
|
Branch |
Woodcliff Lake, NJ |
United States |
Public Sector and Government |
|
|
||
|
Subsidiary |
Porto Salvo |
Portugal |
Biotechnology and Drugs |
23.6 |
44 |
||
|
Mepha -
InvestigaĂ§Ă£o, Desenvolvimento E FabricaĂ§Ă£o FarmacĂªutica, LDA |
Subsidiary |
Porto Salvo, Oeiras |
Portugal |
Biotechnology and Drugs |
51.6 |
67 |
|
|
Subsidiary |
Maroussi |
Greece |
Biotechnology and Drugs |
|
40 |
||
|
Subsidiary |
Basel |
Switzerland |
Biotechnology and Drugs |
14.8 |
35 |
||
|
Subsidiary |
Hackensack, NJ |
United States |
Medical Equipment and Supplies |
113.6 |
30 |
||
|
Subsidiary |
Bucharest |
Romania |
Biotechnology and Drugs |
|
30 |
||
|
Subsidiary |
Roodepoort, Gauteng |
South Africa |
Biotechnology and Drugs |
|
30 |
||
|
Subsidiary |
Lyngby |
Denmark |
Biotechnology and Drugs |
0.0 |
25 |
||
|
Subsidiary |
Asker |
Norway |
Biotechnology and Drugs |
25.0 |
14 |
||
|
Subsidiary |
Tokyo, Minato-ku |
Japan |
Biotechnology and Drugs |
|
13 |
||
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
13 |
||
|
Subsidiary |
Utrecht |
Netherlands |
Biotechnology and Drugs |
213.1 |
11 |
||
|
Subsidiary |
Utrecht, Utrecht |
Netherlands |
Miscellaneous Financial Services |
595.8 |
|
||
|
Subsidiary |
Warszawa |
Poland |
Personal and Household Products |
348.8 |
|
||
|
Subsidiary |
Warszawa |
Poland |
Business Services |
9.5 |
140 |
||
|
Branch |
Waterford |
Ireland |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Haarlem |
Netherlands |
Investment Services |
498.0 |
|
||
|
Subsidiary |
Exeter, NH |
United States |
Biotechnology and Drugs |
33.6 |
|
||
|
Branch |
Mumbai, Maharashtra |
India |
Biotechnology and Drugs |
1.3 |
|
||
|
Subsidiary |
Nagoya |
Japan |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Noida |
India |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Montevideo |
Uruguay |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Guayama, PR |
United States |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Utrecht |
Netherlands |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Belgrade |
Serbia |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Krakow |
Poland |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Haarlem |
Netherlands |
Biotechnology and Drugs |
|
|
||
|
Subsidiary |
Singapore |
Singapore |
Business Services |
|
|
||
|
Subsidiary |
Singapore |
Singapore |
Miscellaneous Capital Goods |
|
5 |
||
|
BARR Pharmaceuticals Inc |
Subsidiary |
|
|
|
|
|
|
|
Subsidiary |
Zagreb |
Croatia |
Biotechnology and Drugs |
|
6,137 |
||
|
Subsidiary |
East Hanover, NJ |
United States |
Biotechnology and Drugs |
|
500 |
||
|
Subsidiary |
Pomona, NY |
United States |
Biotechnology and Drugs |
|
173 |
||
|
Subsidiary |
Woodcliff Lake, NJ |
United States |
Biotechnology and Drugs |
249.1 |
150 |
||
|
|
|
|
|
|
|
|
Executive report
|
Executives |
|
|
|
|
|||
|
Managing director |
Managing Director |
|
|||
|
Managing director |
Managing Director |
|
|||
|
Managing director |
Managing Director |
|
|||
|
Managing director |
Managing Director |
|
|||
|
Managing director |
Managing Director |
|
Annual Profit & Loss
|
|
31-Dec-2011 |
|
Period Length |
12 Months |
|
Filed Currency |
EUR |
|
Exchange Rate
(Period Average) |
0.71919 |
|
Consolidated |
No |
|
|
|
|
Total income |
1,193.8 |
|
Raw materials and services |
875.0 |
|
Net sales |
1,193.8 |
|
Change in stock |
1.8 |
|
Other operating income |
36.4 |
|
Raw materials and consumables employed |
875.0 |
|
Cost of goods sold |
875.0 |
|
Cost of raw materials |
875.0 |
|
Taxes and social security costs |
23.2 |
|
Total payroll costs |
145.4 |
|
Fixed asset depreciation and amortisation |
24.6 |
|
Other operating costs |
156.6 |
|
Net operating
income |
30.3 |
|
Interest received from loans |
0.0 |
|
Other income |
9.9 |
|
Interest payable on loans |
29.4 |
|
Other expenses |
0.0 |
|
Total expenses |
-271.4 |
|
Profit before tax |
301.7 |
|
Extraordinary income |
0.9 |
|
Provisions |
56.0 |
|
Extraordinary result |
0.9 |
|
Other taxes |
1.4 |
|
Total taxation |
0.0 |
|
Profit distributed to shareholders |
-301.2 |
Annual Balance Sheet
Financials in: USD (mil)
|
|
31-Dec-2011 |
|
Filed Currency |
EUR |
|
Exchange Rate |
0.770327 |
|
Consolidated |
No |
|
|
|
|
Issued capital |
0.6 |
|
Capital reserves |
2,564.8 |
|
Total reserves |
0.3 |
|
Profits for the year |
5.8 |
|
Total
stockholders equity |
2,571.5 |
|
Deferred taxation |
0.0 |
|
Other provisions |
46.1 |
|
Provision for pensions |
6.2 |
|
Provisions and allowances |
52.3 |
|
Total long-term
liabilities |
0.0 |
|
Trade creditors |
125.4 |
|
Taxation and social security |
2.9 |
|
Due to group companies |
874.1 |
|
Total current
liabilities |
1,002.3 |
|
Total
liabilities (including net worth) |
3,626.2 |
|
Patents |
2.6 |
|
Intangibles |
2.6 |
|
Land and buildings |
2.4 |
|
Machinery and tools |
39.7 |
|
Fixtures and equipment |
2.4 |
|
Fixed assets under construction |
18.5 |
|
Total tangible
fixed assets |
81.0 |
|
Shares held in associated companies |
2,612.8 |
|
Total financial
assets |
2,612.8 |
|
Total
non-current assets |
2,696.3 |
|
Raw materials |
90.5 |
|
Work in progress |
68.4 |
|
Finished goods |
296.4 |
|
Prepayments |
1.5 |
|
Net stocks and work in progress |
456.7 |
|
Trade debtors |
35.7 |
|
Other receivables |
24.0 |
|
Total
receivables |
468.7 |
|
Owing from associated companies |
409.0 |
|
Cash and liquid assets |
3.0 |
|
Total current
assets |
928.4 |
|
Prepaid expenses and deferred costs |
1.2 |
|
Total assets |
3,626.2 |
Annual Ratios
Financials in: USD (mil)
|
|
31-Dec-2011 |
|
Period Length |
12 Months |
|
Filed Currency |
EUR |
|
Exchange Rate |
0.770327 |
|
Consolidated |
No |
|
|
|
|
Current ratio |
9.26 |
|
Acid test ratio |
4.71 |
|
Total liabilities to net worth |
0.04% |
|
Net worth to total assets |
0.07% |
|
Current liabilities to net worth |
0.04% |
|
Current liabilities to stock |
0.22% |
|
Fixed assets to net worth |
0.10% |
|
Collection period |
117.00 |
|
Stock turnover rate |
4.10 |
|
Profit margin |
0.03% |
|
Return on assets |
0.01% |
|
Shareholders' return |
0.01% |
|
Sales per employee |
51.41 |
|
Profit per employee |
12.93 |
|
Average wage per employee |
6.26 |
|
Net worth |
2,571.5 |
|
Number of employees |
1,670 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.99 |
|
UK Pound |
1 |
Rs.84.19 |
|
Euro |
1 |
Rs.71.86 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.